Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

S095018 · S-95018

Monoclonal antibody · Antagonist of T-cell immunoglobulin and mucin domain-containing protein 3 (HAVCR2)

Phase 1/2 Most advanced trial
1 Registered trials

What is S095018?

S095018 is a recombinant, fully human monoclonal antibody that binds TIM-3, an inhibitory immune checkpoint receptor expressed on certain T cells, including tumor infiltrating lymphocytes. By blocking TIM-3, it abrogates T-cell inhibition and enhances T-cell-mediated tumor cell killing. It is being studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
S-95018
Drug type
Monoclonal antibody
Targets
T-cell immunoglobulin and mucin domain-containing protein 3 (HAVCR2)
Mechanism
Antagonist of T-cell immunoglobulin and mucin domain-containing protein 3 (HAVCR2)
Pathways
T-cell inhibition abrogation, antigen-specific T-lymphocyte activation, cytotoxic T-cell-mediated tumor cell lysis
Therapy area
Oncology
In trials of
REGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
9GEU9XHE20

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06162572 Phase 1/2 Non-small Cell Lung Cancer (NSCLC) Active not recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-small Cell Lung Cancer (NSCLC)

Other drugs acting on HAVCR2

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.